JOINT FILING AGREEMENTJoint Filing Agreement • July 8th, 2015 • Celgene Rivot LTD • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value $0.0001 per share, of Juno Therapeutics, Inc. The undersigned also agree that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
